Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

HIC1 (Hypermethylated in Cancer 1)

Identity

Other namesZBTB29
HGNC HIC1
Location 17p13.3.
Location_base_pair Starts at 1906354 and ends at 1909731 bp from pter ( according to hg18-Mar_2006).
Local_order Close to the D17S5/D17S30/YNZ22 micro satellite marker which is a highly polymorphic variable number of tandem repeats (VNTR) marker. Aberrant hypermethylation in tumours of a cluster of methylation-sensitive NotI restriction sites surrounding this marker allowed the positional cloning of HIC1 in 1995.
Telomere, OVCA1/DPH2L1, OVCA2, HIC1, KIAA0732,......Centromere.
Note OVCA1/DPH2L1 and OVCA2 are two tumour suppressor genes deleted in ovarian cancers.

DNA/RNA

Description The HIC1 gene extends approximately 15 Kbp and consists of four exons. The first three exons 1a, 1b and 1c are alternative. Note that exon 1a is included in exon 1c. The major transcripts are derived from alternative promoters associated with exon 1a and 1b. Exon 1c is conserved in rodent genomes (rat and mice) but transcripts containing it are very minor.
The fourth exon, exon 2, contains the coding region and the 3' untranslated region.
An in-frame upstream ATG initiation codon is also found in exon 1b. This upstream reading frame is conserved in mice.
Transcription 3.0Kb mRNA.
Pseudogene No known pseudogene.

Protein

Description 714 amino acids; around 80kDa; Transcription factor belonging to the BTB/POZ and Krüppel C2H2 zinc fingers family. There is no experimental evidence for the existence of a protein initiated by the upstream ATG (e.g. through the use of antipeptide specific antibodies).
Expression Based on Northern Blots and RT-PCR experiments, HIC1 is widely expressed in various normal tissues.
Localisation Nucleus. Localized on nuclear dots upon overexpression by transient transfection assays in COS-7 or HEK293 cells. In human primary fibroblats (WI38), the endogenous HIC1 proteins are localized in discrete nuclear structures called "HIC1 bodies".
Function HIC1 is a transcriptional repressor belonging to the BTB/POZ and Krüppel C2H2 family (44 proteins in the human genome). HIC1 interacts with the corepressor CtBP through a conserved GLDLSKK motif in the central region. This central region also contains a SUMOylation site MK314HEP which is important for the transcriptional repression potential of HIC1. This K314 is also subject to a reversible acetylation/deacetylation implicating CBP/P300 and the NAD+ dependent class III deacetylase SIRT1.
Homology HIC1 shares distant homology through the conserved BTB/POZ domain and C2H2 zinc fingers domain with several BTB/POZ transcriptional repressors.

Mutations

Epigenetics There are a number of reports highlighting differences in promoter methylation status in primary human tumours (breast, ovaries, prostate, .....) compared to matched normal tissues, hence the name of the gene.
Germinal No germinal coding sequence mutation have been described for HIC1.
Somatic No somatic coding sequence mutations have been described for HIC1 with one exception. During the screening of a panel of 68 medulloblastomas using SSCP analyses, a 12-bp deletion in the second exon of HIC1 has been identified. This results in a deletion of 4 glycine residues in a stretch of 8 located just after the BTB/POZ domain. The other regions of the protein specially the downstream central region and the zinc fingers domain are not affected by this deletion.

Implicated in

Entity medulloblastomas, breast tumours, ovary tumours, prostate tumours
Note (see above)
  

Breakpoints

Note No breakpoint in HIC1 identified so far.

To be noted

A paralog called HIC2, HRG22 or KIAA1020 is found on human chromosome 22. It is located in 22q11.2 in a region subject to translocations (BCRL-2 for Breakpoint Cluster Region-Like 2). But so far, there is no experimental evidence for a translocation implicating HRG22 or for its aberrant hypermethylation in tumours.

External links

Nomenclature
HGNCHIC1   4909
Entrez_GeneHIC1  3090  hypermethylated in cancer 1
Cards
AtlasHIC1ID40819ch17p13
GeneCardsHIC1
EnsemblHIC1 [Search_View]   ENSG00000177374 [Gene_View]
GenatlasHIC1
GeneLynxHIC1
eGenomeHIC1
euGene3090
Genomic and cartography
GoldenPathHIC1  -  17p13.3.   chr17:1906354-1909731 +  17p13.3   [Description]    (hg18-Mar_2006)
EnsemblHIC1 - 17p13.3 [CytoView]
NCBIMapview
OMIMDisease map [OMIM]
HomoloGeneHIC1
Gene and transcription
GenbankAJ550616 [ ENTREZ ]
GenbankAJ583693 [ ENTREZ ]
GenbankAJ583694 [ ENTREZ ]
GenbankBC030208 [ ENTREZ ]
GenbankBC156194 [ ENTREZ ]
RefSeqNM_001098202 [ SRS ]    NM_001098202 [ ENTREZ ]
RefSeqNM_006497 [ SRS ]    NM_006497 [ ENTREZ ]
RefSeqAC_000060 [ SRS ]    AC_000060 [ ENTREZ ]
RefSeqAC_000149 [ SRS ]    AC_000149 [ ENTREZ ]
RefSeqNC_000017 [ SRS ]    NC_000017 [ ENTREZ ]
RefSeqNT_010718 [ SRS ]    NT_010718 [ ENTREZ ]
RefSeqNW_001838403 [ SRS ]    NW_001838403 [ ENTREZ ]
RefSeqNW_926584 [ SRS ]    NW_926584 [ ENTREZ ]
AceViewHIC1 AceView - NCBI
UnigeneHs.695682 [ SRS ]    Hs.695682 [ NCBI ]     HS695682 [ spliceNest ]
Fast-db736 (alternative variants)
Protein : pattern, domain, 3D structure
SwissProtO95459 [ SRS]    O95459 [ EXPASY ]     O95459 [ INTERPRO ]     O95459 [ UNIPROT ]
PrositePS00028 ZINC_FINGER_C2H2_1 [ SRS ]    PS00028 ZINC_FINGER_C2H2_1 [ Expasy ]
PrositePS50157 ZINC_FINGER_C2H2_2 [ SRS ]    PS50157 ZINC_FINGER_C2H2_2 [ Expasy ]
InterproIPR007087 Znf_C2H2 [ SRS ]    IPR007087 Znf_C2H2 [ EBI ]
InterproIPR015880 Znf_C2H2-like [ SRS ]    IPR015880 Znf_C2H2-like [ EBI ]
CluSTrO95459
SmartSM00355 ZnF_C2H2 [EMBL]
BlocksO95459
HPRD04826
Protein Interaction databases
DIPO95459
IntActO95459
Polymorphism : SNP, mutations, diseases
OMIM603825    [ map ]   
GENECLINICS603825
SNPHIC1 [dbSNP-NCBI]  
SNPNM_001098202 [SNP-NCI]  
SNPNM_006497 [SNP-NCI]  
SNPHIC1 [GeneSNPs - Utah]  HIC1] [HGBASE - SRS]
HAPMAPHIC1 [HAPMAP]  
HGMDHIC1
General knowledge
Family BrowserHIC1 [UCSC Family Browser]
SOURCENM_001098202
SOURCENM_006497
SMDHs.695682
SAGEHs.695682
GOtranscription factor activity [Amigo]  transcription factor activity
GOprotein binding [Amigo]  protein binding
GOintracellular [Amigo]  intracellular
GOnucleus [Amigo]  nucleus
GOtranscription [Amigo]  transcription
GOregulation of transcription, DNA-dependent [Amigo]  regulation of transcription, DNA-dependent
GOmulticellular organismal development [Amigo]  multicellular organismal development
GOzinc ion binding [Amigo]  zinc ion binding
GOnegative regulation of cell cycle [Amigo]  negative regulation of cell cycle
GOmetal ion binding [Amigo]  metal ion binding
BIOCARTAHypoxia and p53 in the Cardiovascular system    [Genes]
PubGeneHIC1
TreeFamHIC1
CTD3090 [Comparative ToxicoGenomics Database]
Other databases
Probes
ProbeHIC1 Related clones (RZPD - Berlin)
PubMed
PubMed23 Pubmed reference(s) in Entrez

Bibliography

p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.
Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB
Nature medicine. 1995 ; 1 (6) : 570-577.
PMID 7585125
 
Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.
Deltour S, Guerardel C, Leprince D
Proceedings of the National Academy of Sciences of the United States of America. 1999 ; 96 (26) : 14831-14836.
PMID 10611298
 
Isolation and embryonic expression of the novel mouse gene Hic1, the homologue of HIC1, a candidate gene for the Miller-Dieker syndrome.
Grimm C, Spˆrle R, Schmid TE, Adler ID, Adamski J, Schughart K, Graw J
Human molecular genetics. 1999 ; 8 (4) : 697-710.
PMID 10072440
 
Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome.
Carter MG, Johns MA, Zeng X, Zhou L, Zink MC, Mankowski JL, Donovan DM, Baylin SB
Human molecular genetics. 2000 ; 9 (3) : 413-419.
PMID 10655551
 
Characterization of HRG22, a human homologue of the putative tumor suppressor gene HIC1.
Deltour S, Pinte S, Guˆİrardel C, Leprince D
Biochemical and biophysical research communications. 2001 ; 287 (2) : 427-434.
PMID 11554746
 
Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53.
Guerardel C, Deltour S, Pinte S, Monte D, Begue A, Godwin AK, Leprince D
The Journal of biological chemistry. 2001 ; 276 (5) : 3078-3089.
PMID 11073960
 
The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif.
Deltour S, Pinte S, Guerardel C, Wasylyk B, Leprince D
Molecular and cellular biology. 2002 ; 22 (13) : 4890-4901.
PMID 12052894
 
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors.
Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB
Nature genetics. 2003 ; 33 (2) : 197-202.
PMID 12539045
 
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.
Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB
Cancer cell. 2004 ; 6 (4) : 387-398.
PMID 15488761
 
Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1.
Pinte S, Guˆİrardel C, Deltour-Balerdi S, Godwin AK, Leprince D
Oncogene. 2004 ; 23 (22) : 4023-4031.
PMID 15007385
 
The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties.
Pinte S, Stankovic-Valentin N, Deltour S, Rood BR, Guˆİrardel C, Leprince D
The Journal of biological chemistry. 2004 ; 279 (37) : 38313-38324.
PMID 15231840
 
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses.
Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB
Cell. 2005 ; 123 (3) : 437-448.
PMID 16269335
 
Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1.
Britschgi C, Rizzi M, Grob TJ, Tschan MP, Hˆşgli B, Reddy VA, Andres AC, Torbett BE, Tobler A, Fey MF
Oncogene. 2006 ; 25 (14) : 2030-2039.
PMID 16301995
 
A L225A substitution in the human tumour suppressor HIC1 abolishes its interaction with the corepressor CtBP.
Stankovic-Valentin N, Verger A, Deltour-Balerdi S, Quinlan KG, Crossley M, Leprince D
The FEBS journal. 2006 ; 273 (13) : 2879-2890.
PMID 16762039
 
HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies.
Valenta T, Lukas J, Doubravska L, Fafilek B, Korinek V
The EMBO journal. 2006 ; 25 (11) : 2326-2337.
PMID 16724116
 
An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity.
Stankovic-Valentin N, Deltour S, Seeler J, Pinte S, Vergoten G, Guˆİrardel C, Dejean A, Leprince D
Molecular and cellular biology. 2007 ; 27 (7) : 2661-2675.
PMID 17283066
 
Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex.
Zhang Q, Wang SY, Fleuriel C, Leprince D, Rocheleau JV, Piston DW, Goodman RH
Proceedings of the National Academy of Sciences of the United States of America. 2007 ; 104 (3) : 829-833.
PMID 17213307
 
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written02-2007Dominique Leprince

Citation

This paper should be referenced as such :
Leprince D . HIC1 (Hypermethylated in Cancer 1). Atlas Genet Cytogenet Oncol Haematol. February 2007 .
URL : http://AtlasGeneticsOncology.org/Genes/HIC1ID40819ch17p13.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Oct 14 21:19:52 2008


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

j.l.huret@chu-poitiers.fr.